| Budget Amount *help |
¥43,550,000 (Direct Cost: ¥33,500,000、Indirect Cost: ¥10,050,000)
Fiscal Year 2015: ¥8,710,000 (Direct Cost: ¥6,700,000、Indirect Cost: ¥2,010,000)
Fiscal Year 2014: ¥14,690,000 (Direct Cost: ¥11,300,000、Indirect Cost: ¥3,390,000)
Fiscal Year 2013: ¥20,150,000 (Direct Cost: ¥15,500,000、Indirect Cost: ¥4,650,000)
|
|---|
| Outline of Final Research Achievements |
We generated 55 organoid lines from colorectal neoplasms, including serrated lesions and MSI colon cancers, and elaborated their biological properties. The organoids pathophysiologically recapitulated the patient tumors and exhibited unique gene expression and genetic mutation patterns. MSI colon cancers harbored substantial number of non-synonymous mutations, allowing their robust growth in hostile conditions with poor growth factors. Similar property of the MSI colon cancer organodis was observed in the xenograft models, in which the MSI colon cancer organoids displayed significantly higher tumorigenic capacity. These data suggested that the MSI colorectal cancers distinctively differ from the other sporadic colorectal cancers in molecular and biological characters, highlighting the significance of the individual therapeutics toward eradication of the MSI colorectal cancers.
|
